X4 Pharmaceuticals, Inc (XFOR) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, X4 Pharmaceuticals, Inc's filing signal turned negative.

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare hematology diseases. Its primary asset is mavorixafor, an oral small molecule antagonist of the CXCR4 chemokine receptor, marketed as XOLREMDI(R) for WHIM syndrome in the U.S. The company is advancing mavorixafor in a pivotal Phase 3 trial (4WARD) for chronic neutropenia (CN), a rare blood disorder. X4 Pharmaceuticals has undergone significant restructuring, including workforce reductions, to focus resources on the CN indication. The company has secured substantial funding through equity offerings, ending 2025 with $253.0 million in cash, cash equivalents, and marketable securities.

Revenue is primarily driven by net product sales of XOLREMDI(R) for WHIM syndrome and license revenue from collaborations, such as the agreement with Norgine for European territories.